title: Oral antibiotic therapy improves fat absorption in cystic fibrosis patients with small intestine bacterial overgrowth.
abstract: BACKGROUND
  The aim of the present study was to assess the influence of antibiotic therapy on fat assimilation in cystic fibrosis (CF) patients with small intestine bacterial overgrowth (SIBO).
  
  
  METHODS
  Twenty six pancreatic insufficient CF patients with bronchopulmonary exacerbation and diagnosed SIBO (positive hydrogen-methane breath test) entered the study. (13)C mixed triglyceride breath test was performed before and after antibiotic therapy. Sixteen subjects were treated intravenously (ceftazidime and amikacin), ten patients orally (ciprofloxacin).
  
  
  RESULTS
  Cumulative percentage dose recovery changed significantly in the subgroup receiving antibiotics orally [median (mean±SEM): 3.6% (4.5±1.3%) vs. 7.2 (6.9±1.6%); p=0.019]. In the subgroup with intravenous drug administration, the tendency towards improvement was noted [2.7 (4.3±1.5%) vs. 5.2 (5.7±0.8%); p=0.109].
  
  
  CONCLUSIONS
  Antibiotic therapy applied in CF patients with SIBO in the course of pulmonary exacerbation results in a significant improvement of fat digestion and absorption.
authors.affiliation: 1st Chair of Pediatrics, Department of Pediatric Gastroenterology & Metabolism, Poznań University of Medical Sciences, Szpitalna 27/33; 60-572 Poznań, Poland. alisow1@wp.pl
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Lisowska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Pogorzelski
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Oracz
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Siuda
authors.forename: Wojciech
authors.initials: W
authors.lastname: Skorupa
authors.forename: Marta
authors.initials: M
authors.lastname: Rachel
authors.forename: Szczepan
authors.initials: S
authors.lastname: Cofta
authors.forename: Tomasz
authors.initials: T
authors.lastname: Piorunek
authors.forename: Jarosław
authors.initials: J
authors.lastname: Walkowiak
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002648:Child; D003550:Cystic Fibrosis / Q000378:metabolism* / Q000382:microbiology*; D004041:Dietary Fats / Q000378:metabolism*; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D007421:Intestine, Small / Q000378:metabolism* / Q000382:microbiology*; D008297:Male; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D004041:Dietary Fats